Cargando…

O4.5. LONG TERM EFFECTS OF EARLY INTERVENTION SERVICES FOR FIRST EPISODE PSYCHOSIS: OUTCOMES OVER FIVE YEARS FROM THE RECOVERY AFTER A 1ST EPISODE OF SCHIZOPHRENIA-EARLY TREATMENT PROGRAM (RAISE-ETP)

BACKGROUND: Early intervention services (EIS) for first episode psychosis (FEP) are now implemented worldwide and these integrated and team-based treatment programs improve FEP outcomes while patients are participating. EIS service and treatment models provide care for limited periods followed by re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robinson, Delbert, Schooler, Nina, Kane, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Oral Session: Digital Health/Methods
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233867/ http://dx.doi.org/10.1093/schbul/sbaa028.022

Ejemplares similares

O4.2. THE PREVENTION OF RELAPSE AND HOSPITALIZATION IN FIRST EPISODE AND EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE PRELAPSE TRIAL
por: Kane, John, et al.
Publicado: (2020)

O9.7. TECHNOLOGY ASSISTED RELAPSE PREVENTION PROGRAM REDUCES HOSPITALIZATION IN SCHIZOPHRENIA PATIENTS AT HIGH RISK FOR RELAPSE
por: Schooler, Nina, et al.
Publicado: (2020)

T255. WHO PARTICIPATED IN FAMILY WORK IN THE US RAISE-ETP FIRST EPISODE SAMPLE?
por: Glynn, Shirley, et al.
Publicado: (2018)

O3.5. EARLY TRAJECTORIES OF POSITIVE SYMPTOMS REMISSION IN FIRST EPISODE-PSYCHOSIS: A 2-YEAR FOLLOW-UP STUDY
por: Percie du Sert, Olivier, et al.
Publicado: (2020)

O6.1. COGNITIVE CONTROL DIFFERENCES BETWEEN TREATMENT RESPONSIVE AND TREATMENT RESISTANT FIRST-EPISODE PSYCHOSIS PATIENTS
Publicado: (2020)

O5.3. IMPAIRED LEFT TEMPORAL-PARIETAL JUNCTION FMRI ACTIVITY DURING CATEGORY FLUENCY IN FIRST-EPISODE PSYCHOSIS
por: Perumaly, Leana, et al.
Publicado: (2020)

O4.1. AEROBIC EXERCISE DOSE DETERMINES THE COGNITIVE GAIN IN FIRST-EPISODE SCHIZOPHRENIA, SO HOW DO WE ENCOURAGE SUFFICIENT EXERCISE?
por: Nuechterlein, Keith, et al.
Publicado: (2020)

O5.4. THALAMIC CONNECTIVITY IN EARLY PSYCHOSIS DURING TASK AND AT REST
por: Berge, Daniel, et al.
Publicado: (2020)

O8.2. VALIDATION OF A COMPUTERIZED ADAPTIVE TESTING TOOL FOR PSYCHOSIS: THE CAT-PSYCHOSIS BATTERY
por: Guinart, Daniel, et al.
Publicado: (2020)

O2.5. CORTICAL PATTERNING OF ABNORMAL MORPHOMETRIC SIMILARITY IN PSYCHOSIS IS ASSOCIATED WITH BRAIN EXPRESSION OF SCHIZOPHRENIA-RELATED GENES
Publicado: (2020)

O6.3. ASSOCIATIONS BETWEEN COGNITIVE FUNCTION AND CORTICAL LEVELS OF GLUTAMATE AND GABA IN ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS
por: Bojesen, Kirsten, et al.
Publicado: (2020)

O6.4. ASSOCIATION BETWEEN CLUSTERS OF FORMAL THOUGHT DISORDERS SEVERITY AND NEUROCOGNITIVE AND FUNCTIONAL OUTCOME INDICES IN THE EARLY STAGES OF PSYCHOSIS – RESULTS FROM THE PRONIA COHORT
por: Öztürk, Ömer Faruk, et al.
Publicado: (2020)

F249. FAMILY BURDEN IN THE US RAISE-ETP PROGRAM: TREATMENT EFFECTS AND PREDICTORS
por: Glynn, Shirley, et al.
Publicado: (2018)

O2.2. EVALUATION OF THE RELATIONSHIP BETWEEN GLUTAMATE AND BRAIN CONNECTIVITY IN ANTIPSYCHOTIC-NAïVE FIRST EPISODE PATIENTS – A COMBINED MAGNETIC RESONANCE SPECTROSCOPY AND RESTING STATE FUNCTIONAL CONNECTIVITY MRI STUDY
por: Maximo, Jose, et al.
Publicado: (2020)

O5.2. CBD MODULATION OF HIPPOCAMPAL GLUTAMATE IN PSYCHOSIS
por: O’Neill, Aisling, et al.
Publicado: (2020)

O8.3. DEVELOPMENT AND UTILITY OF THE MAUDSLEY ENVIRONMENTAL RISK SCORE FOR PSYCHOSIS
Publicado: (2020)

O10.6. ANTERIOR VERSUS POSTERIOR HIPPOCAMPUS WITHIN PSYCHOSIS: A BSNIP STUDY
por: del Re, Elisabetta C, et al.
Publicado: (2020)

O1.2. REDUCING THE DURATION OF UNTREATED PSYCHOSIS IN A U.S. CATCHMENT: THE MINDMAP CAMPAIGN
por: Srihari, Vinod, et al.
Publicado: (2020)

O2.3. ABNORMAL BRAIN AGING IN YOUTH WITH SUBCLINICAL PSYCHOSIS AND OBSESSIVE-COMPULSIVE SYMPTOMS
por: Cropley, Vanessa, et al.
Publicado: (2020)

Prodromal phase and first episode psychosis in schizophrenia: early signs and diagnosis
por: Buciuc, A.-G., et al.
Publicado: (2022)

O3.4. PSYCHOSIS PHENOTYPES FROM B-SNIP FOR CLINICAL ADVANCES: BIOTYPE CHARACTERISTICS AND TARGETS
por: Clementz, Brett, et al.
Publicado: (2020)

O6.6. MULTIMODAL PROGNOSIS OF NEGATIVE SYMPTOM SEVERITY IN INDIVIDUALS WITH INCREASED RISK OF DEVELOPING PSYCHOSIS
por: Hauke, Daniel, et al.
Publicado: (2020)

O10.4. THE ROLE OF CONTEXTUAL FACTORS AND ASSESSMENT STRATEGIES IN THE ACCURATE SCREENING OF PSYCHOSIS-RISK SYMPTOMS
por: Schiffman, Jason, et al.
Publicado: (2020)

O9.3. CANNABIS CONSUMPTION INCREASES RISK OF PSYCHOSIS IN A SUBGROUP OF PATIENTS WITH HIGH PERIPHERAL BLOOD INFLAMMATION
por: Corsi-Zuelli, Fabiana, et al.
Publicado: (2020)

O11.4. INTERACTOME OVERLAP BETWEEN SCHIZOPHRENIA AND COGNITION
por: Koch, Elise, et al.
Publicado: (2020)

O5.6. ADVANCED DIFFUSION IMAGING IN PSYCHOSIS RISK: A CROSS-SECTIONAL AND LONGITUDINAL STUDY OF WHITE MATTER DEVELOPMENT
por: Di Biase, Maria, et al.
Publicado: (2020)

O7.5. STANDARDIZED MORTALITY RATIOS IN EARLY- AND ADULT ONSET FOR THREE DISORDERS
por: Lammers Vernal, Ditte, et al.
Publicado: (2020)

O11.2. ELEVATION OF MACROPHAGE-RELATED TRANSCRIPTS IN THE MIDBRAIN IN SCHIZOPHRENIA
por: Purves-Tyson, Tertia, et al.
Publicado: (2020)

O10.2. DEFICIENT VISUAL ODDBALL STIMULUS PROCESSING PREDICTS PSYCHOSIS ONSET: RESULTS FROM THE NORTH AMERICAN PRODROME LONGITUDINAL STUDY
por: Hamilton, Holly, et al.
Publicado: (2020)

O1.3. BACK TO THE FUTURE: PREDICTING POPULATION NEED FOR PSYCHOSIS CARE BASED ON THE EPIDEMIOLOGY OF PSYCHOTIC DISORDERS IN ENGLAND, AN APPLIED BAYESIAN METHODOLOGY
por: McDonald, Keltie, et al.
Publicado: (2020)

O2.4. FUNCTIONAL CONNECTOME-WIDE ASSOCIATIONS OF SCHIZOPHRENIA POLYGENIC RISK
por: Cao, Hengyi, et al.
Publicado: (2020)

O10.5. CLINICAL HIGH RISK (CHR) CRITERIA IN CHILDREN AND ADOLESCENTS NOT SUSPECTED TO DEVELOP PSYCHOSIS: NO TRANSDIAGNOSTIC SEVERITY MARKER OF MENTAL HEALTH PROBLEMS
por: Schultze-Lutter, Frauke, et al.
Publicado: (2020)

O10.3. EARLY CHILDHOOD DEVELOPMENT AND LATER PSYCHOTIC EXPERIENCES: FINDINGS FROM THE RAINE STUDY
por: Carey, Eleanor, et al.
Publicado: (2020)

O4.6. REAL-TIME FMRI NEUROFEEDBACK FOR TREATMENT REFRACTORY HALLUCINATIONS IN SCHIZOPHRENIA
Publicado: (2020)

O10.1. MATERNAL PRENATAL C-REACTIVE PROTEIN, NEURODEVELOPMENT AND OTHER RISK FACTORS FOR PSYCHOSIS IN ADOLESCENT OFFSPRING IN THE NORTHERN FINLAND BIRTH COHORT 1986
por: Ramsay, Hugh, et al.
Publicado: (2020)

T117. PROMINENT AND PERSISTENT AUTISTIC TRAITS ARE ASSOCIATED WITH EARLY NON-REMISSION IN FIRST-EPISODE SCHIZOPHRENIA
por: Pina-Camacho, Laura, et al.
Publicado: (2020)

O2.1. LOCAL AND LONG-RANGE CONNECTIVITY PATTERNS OF AUDITORY PERCEPTUAL DISTURBANCE IN SCHIZOPHRENIA
por: Hare, Stephanie, et al.
Publicado: (2020)

O6.2. A NETWORK FOR COGNITIVE, MOTOR, AND PSYCHOPATHOLOGICAL ALTERATIONS IN SCHIZOPHRENIA SPECTRUM DISORDERS
por: Moura, Bernardo, et al.
Publicado: (2020)

O5.5. THE NEUROBIOLOGY OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: MULTI-MODAL PET AND FMRI FINDINGS
por: Howes, Oliver, et al.
Publicado: (2020)

O1.4. HOW THE MOST CITED RESEARCH ARTICLES ABOUT SCHIZOPHRENIA IN 2018 DEPICT THE DISEASE?
por: Tonsig, Gabriela, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mnr4s77eh5375u0o5k808r1i3m